Home Mf Research Tata Nifty Midsmall Healthcare Index Fund Regular Plan Growth
Tata Mutual Fund

Tata Nifty MidSmall Healthcare Index Fund - Regular Plan - Growth

Others Solution Oriented Index
Fund House : Tata Mutual Fund
Overview
Returns
Portfolio
SIP Calculator
Analysis
Peer Comparison
Fund Family
Scheme Details
-
-
  • 1W
  • 2W
  • 1M
  • 3M
  • 6M
  • 1Y
  • SI
NAV (as on 2025-06-13)
12.47 0.23%
Fund Size (Total Assets)
-
Expense Ratio (Regular)
1.09%
Expense Ratio (Direct)
0.34%
SIP Returns
Period Invested for ₹1000 SIP Started on Investments Latest Value Abs. Returns
One Week 2025-06-06 ₹1,000.00 ₹1,015.76
1.58 %
Two Week 2025-05-29 ₹1,000.00 ₹1,030.76
3.08 %
1 Month 2025-05-14 ₹1,000.00 ₹1,027.09
2.71 %
Three Months 2025-03-17 ₹3,000.00 ₹3,195.19
6.51 %
Six Months 2024-12-16 ₹6,000.00 ₹6,338.09
5.63 %
One Year 2024-06-13 ₹12,000.00 ₹12,671.97
5.60 %
Since Inception 2024-04-26 ₹14,000.00 ₹15,126.46
8.05 %
Portfolio Summary
Company Name Sector Sector Type Nav(in %)
MAX HEALTHCARE INSTITUTE LTD Healthcare Services equity 15.07
LUPIN LTD Pharmaceuticals & Biotechnology equity 8.52
FORTIS HEALTHCARE LTD Healthcare Services equity 6.63
AUROBINDO PHARMA LTD Pharmaceuticals & Biotechnology equity 5.79
MANKIND PHARMA LTD Pharmaceuticals & Biotechnology equity 5.02
ALKEM LABORATORIES LTD Pharmaceuticals & Biotechnology equity 4.88
LAURUS LABS LTD Pharmaceuticals & Biotechnology equity 4.30
GLENMARK PHARMACEUTICALS LTD Pharmaceuticals & Biotechnology equity 3.95
IPCA LABORATORIES LTD Pharmaceuticals & Biotechnology equity 3.57
KRISHNA INSTITUTE OF MEDICAL SCIENCES LTD Healthcare Services equity 3.03
ABBOTT INDIA LTD Pharmaceuticals & Biotechnology equity 2.86
BIOCON LTD Pharmaceuticals & Biotechnology equity 2.73
GLAXOSMITHKLINE PHARMACEUTICALS LTD Pharmaceuticals & Biotechnology equity 2.46
COHANCE LIFESCIENCES LTD Pharmaceuticals & Biotechnology equity 2.40
PIRAMAL PHARMA LTD Pharmaceuticals & Biotechnology equity 2.29
GLAND PHARMA LTD Pharmaceuticals & Biotechnology equity 2.28
ASTER DM HEALTHCARE LTD Healthcare Services equity 2.27
SYNGENE INTERNATIONAL LTD Healthcare Services equity 2.20
J.B.CHEMICALS & PHARMACEUTICALS LTD Pharmaceuticals & Biotechnology equity 2.17
NARAYANA HRUDAYALAYA LTD Healthcare Services equity 2.13
AJANTA PHARMA LTD Pharmaceuticals & Biotechnology equity 1.90
DR. LAL PATH LABS LTD Healthcare Services equity 1.87
GLOBAL HEALTH LTD Healthcare Services equity 1.78
NEULAND LABORATORIES LTD Pharmaceuticals & Biotechnology equity 1.78
POLY MEDICURE LTD Healthcare Equipment & Supplies equity 1.55
PFIZER LTD Pharmaceuticals & Biotechnology equity 1.53
NATCO PHARMA LTD Pharmaceuticals & Biotechnology equity 1.42
GRANULES INDIA LTD Pharmaceuticals & Biotechnology equity 1.39
RAINBOW CHILDRENS MEDICARE LTD Healthcare Services equity 1.26
ALEMBIC PHARMACEUTICALS LTD Pharmaceuticals & Biotechnology equity 1.03
A) REPO - - 0.15
NET CURRENT LIABILITIES - - -0.21
SIP Calculator
Risk Ratios
Standard Deviation
-
Beta
-
Sharpe Ratio
-
Lock In Period
-
Residual Maturity
-
Standard Deviation:
Standard deviation numbers measure the variability or volatility of a fund's returns over a specific time period (often 3 years).
  • Low standard deviation = Stable, predictable returns → Suitable for conservative investors seeking stability.
  • High standard deviation = High volatility, more risk → Be cautious, suitable for risk-tolerant investors who can handle fluctuations.
Beta:
Beta measures a fund's volatility about the market or a benchmark. A lower beta means the fund's performance is less sensitive to market movements, making it more predictable compared to the market.
  • Low beta = Less sensitive to market changes → Great for investors with less market exposure.
  • High beta = More sensitive to market changes → Better for aggressive investors who seek higher returns but can handle market risks.
Sharpe Ratio:
The Sharpe Ratio measures how much return a fund has made compared to the risk it carries. A higher Sharpe ratio indicates better returns relative to the risk taken, meaning the fund delivers more efficiently.
  • A higher Sharpe ratio indicates better risk-adjusted returns → Look for funds with higher ratios for better return efficiency.
  • Use it to compare different funds' efficiency in generating returns relative to the risk taken.
Lock-In Period:

India's "lock-in period" in mutual funds encourages long-term investment, particularly in tax-saving schemes preventing redemption or selling of units.

Lock-in times for various investment types

  • Most ELSS mutual fund holders hold for 3 years.
  • Tax savings FDs lock in for 5 years.
  • The lock-in period for 8% Government of India bond investment is 6 years.
  • ULIPs must be locked in for 5 years.
  • The average hedge fund holding period is 30-90 days.
  • The average PPF investor holds onto their money for 15 years.
Residual Maturity:

Residual maturity is the remaining time until a security reaches its maturity date. It is an important factor for investors to consider when evaluating the risk associated with an investment.

There are two different types of residual maturity.

  • Short-term residual maturity: This occurs when a security has less than a year left on its maturity.
  • Long-term residual maturity: This occurs when a security has more than a year left on its remaining maturity.
Scheme Details
  • Fund manager(s) : Kapil Menon (20 years),
  • Expense ration regular : 1.09
  • Expense ration direct : 0.34
  • Launch date : -
  • Benchmark : -
  • Min SIP amount : -
  • Max SIP amount : -
  • Min investment amount (one time- first time) : ₹100.00
  • Type : others
Exit load
0.25%

FAQs

Is a Mutual Fund with a Lower NAV Better?
What Are the Charges in Mutual Fund Investments?
What Are the Tax Benefits of Mutual Funds?
Is It a Good Time to Invest in Mutual Funds?
What Is the Difference Between Dividend and Growth Plans?
Should I Invest in Infrastructure Funds?
What Are Sector-Specific Funds/Schemes?
What Happens If I Miss an SIP Payment?
How Can I Compare Different Mutual Funds?